Analysis of the iron states in iron-containing pharmaceutical products using Mössbauer spectroscopy

Irina V. Alenkina; Andrey V. Chukin; Gregory Leitus; Olga V. Denisova; Maria Gracheva; Israel Felner; Ernő Kuzmann; Zoltán Homonnay; Michael I. Oshtrakh

doi:10.1016/j.jpba.2023.115745

Analysis of the iron states in iron-containing pharmaceutical products using Mössbauer spectroscopy

Irina V. Alenkina, Andrey V. Chukin, Gregory Leitus, Olga V. Denisova, Maria Gracheva, Israel Felner, Ernő Kuzmann, Zoltán Homonnay, Michael I. Oshtrakh^*

^*Corresponding author for this work

Department of Chemical Research Support

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon® with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex® and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by ⁵⁷Fe Mössbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by Mössbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.

Original language	English
Article number	115745
Number of pages	15
Journal	Journal of Pharmaceutical and Biomedical Analysis
Volume	237
DOIs	https://doi.org/10.1016/j.jpba.2023.115745
Publication status	Published - 5 Jan 2024

Bibliographical note

The authors wish to thank Dr. I. Popov (Head of the Unit for Nanocharacterization, Faculty of Science, The Hebrew University, Jerusalem, Israel) for her kind help with interpretation of XRD data. This work was supported by the Ministry of Science and Higher Education of the Russian Federation , project No. FEUZ-2023-0013 . M.I.O. and I.V.A. gratefully acknowledge the Ural Federal University Program of Development within the Priority-2030 Program (research funding from the Ministry of Science and Higher Education of the Russian Federation). This work was carried out within the Agreement of Cooperation between the Ural Federal University (Ekaterinburg) and the Eötvös Loránd University (Budapest).

All Science Journal Classification (ASJC) codes

Analytical Chemistry
Pharmaceutical Science
Drug Discovery
Spectroscopy
Clinical Biochemistry

Access to Document

10.1016/j.jpba.2023.115745

Cite this

@article{248b0cec863742cdb814e17c32cb4a34,

title = "Analysis of the iron states in iron-containing pharmaceutical products using M{\"o}ssbauer spectroscopy",

abstract = "Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon{\textregistered} with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex{\textregistered} and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by 57Fe M{\"o}ssbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by M{\"o}ssbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.",

author = "Alenkina, {Irina V.} and Chukin, {Andrey V.} and Gregory Leitus and Denisova, {Olga V.} and Maria Gracheva and Israel Felner and Ern{\H o} Kuzmann and Zolt{\'a}n Homonnay and Oshtrakh, {Michael I.}",

note = "The authors wish to thank Dr. I. Popov (Head of the Unit for Nanocharacterization, Faculty of Science, The Hebrew University, Jerusalem, Israel) for her kind help with interpretation of XRD data. This work was supported by the Ministry of Science and Higher Education of the Russian Federation , project No. FEUZ-2023-0013 . M.I.O. and I.V.A. gratefully acknowledge the Ural Federal University Program of Development within the Priority-2030 Program (research funding from the Ministry of Science and Higher Education of the Russian Federation). This work was carried out within the Agreement of Cooperation between the Ural Federal University (Ekaterinburg) and the E{\"o}tv{\"o}s Lor{\'a}nd University (Budapest).",

year = "2024",

month = jan,

day = "5",

doi = "10.1016/j.jpba.2023.115745",

language = "English",

volume = "237",

journal = "Journal of Pharmaceutical and Biomedical Analysis",

issn = "0731-7085",

publisher = "Elsevier Science",

}

TY - JOUR

T1 - Analysis of the iron states in iron-containing pharmaceutical products using Mössbauer spectroscopy

AU - Alenkina, Irina V.

AU - Chukin, Andrey V.

AU - Leitus, Gregory

AU - Denisova, Olga V.

AU - Gracheva, Maria

AU - Felner, Israel

AU - Kuzmann, Ernő

AU - Homonnay, Zoltán

AU - Oshtrakh, Michael I.

N1 - The authors wish to thank Dr. I. Popov (Head of the Unit for Nanocharacterization, Faculty of Science, The Hebrew University, Jerusalem, Israel) for her kind help with interpretation of XRD data. This work was supported by the Ministry of Science and Higher Education of the Russian Federation , project No. FEUZ-2023-0013 . M.I.O. and I.V.A. gratefully acknowledge the Ural Federal University Program of Development within the Priority-2030 Program (research funding from the Ministry of Science and Higher Education of the Russian Federation). This work was carried out within the Agreement of Cooperation between the Ural Federal University (Ekaterinburg) and the Eötvös Loránd University (Budapest).

PY - 2024/1/5

Y1 - 2024/1/5

N2 - Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon® with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex® and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by 57Fe Mössbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by Mössbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.

AB - Iron-containing pharmaceuticals, namely: (i) PreNatal with ferrous fumarate, (ii) Tardyferon® with ferrous sulfate, (iii) Fenules with water free ferrous sulfate, (iv) Iron Complex with iron glycinate, citrate, (v) Gentle Iron, (vi) Hema-Plex® and (vii) Iron Bisglycinate with iron (ferrous) bisglycinate chelate (iron compounds are given as declared by the manufactures) were studied by 57Fe Mössbauer spectroscopy with X-ray diffraction and magnetization measurements for analysis of the iron state. The obtained results demonstrate that the iron compound announced by the manufacturer in each pharmaceutical is not homogeneous and exists as some modifications of this compound or results of its transformation/oxidation probably due to its instability. The presence of ferrous and ferric compounds is observed, and the relative ferric iron fractions are roughly determined for each pharmaceutical product. This analysis clearly shows the differences between the iron compounds proclaimed by the manufacturers and those obtained by Mössbauer spectroscopy. That justifies as to why this technique should be used for the control and analysis of the iron-containing pharmaceuticals.

UR - http://www.scopus.com/inward/record.url?scp=85173271405&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2023.115745

DO - 10.1016/j.jpba.2023.115745

M3 - Article

C2 - 37832473

AN - SCOPUS:85173271405

SN - 0731-7085

VL - 237

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

M1 - 115745

ER -

Analysis of the iron states in iron-containing pharmaceutical products using Mössbauer spectroscopy

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this